Abstract: A composition of a polyamide and PTFE produces a lubricious surface on extruded medical tubing. The small size of the PTFE powder when compounded with polyamide disperses uniformly and produces an intrinsically lubricious polymer. Such a composition can be useful in medical, intralumenal tubing.

Abstract: The medical devices of the present invention include self-reinforcing polymer materials, based on the rigid-rod paraphenylene copolymer chemistry. Accordingly, the materials of the present invention provide a unique combination of physical properties that are advantageous for use in various medical devices. The medical devices may include those for maneuvering through the body passages of a patient, such as for example the circulatory system, to a desired site for treatment.

Abstract: An exhaust gas treatment system having an exhaust gas inlet section, an oxygen enrichment system, catalyst holding arms, and an exhaust gas outlet section is disclosed. The exhaust gas inlet and outlet sections can be designed to mate to existing exhaust gas plumbing systems for industrial facilities. The optional oxygen enrichment system helps optimize catalytic performance by maintaining excess oxygen in the exhaust gas stream and by imparting greater turbulence to the exhaust gas stream. Disposed within each catalyst holding arm is at least one catalyst coated substrate where the catalytic oxidation of formaldehyde and other volatile organic compounds occurs. The catalytic substrate can be catalyst coated bricks, particles, beads, fabrics, or filter materials. Each catalyst holding arm can be selectively closed off using upstream and downstream isolation valves. Catalyst coated substrate longevity can be increased by the inclusion of an optional filter upstream of the catalyst coated substrates.

Abstract: A method of treating at least one symptom or condition associated with but not limited to: 1) Substance-Related Disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Withdrawal, Alcohol-Related Disorders, Amphetamine (or Amphetamine-Like)-Related Disorders, Caffeine-Related Disorders, Cannabis-Related Disorders, Cocaine-Related Disorders, Hallucinogen-Related Disorders, Inhalant-Related Disorders, Nicotine-Related Disorders, Opioid-Related Disorders, Phencyclidine (or Phencyclidine-Like)-Related Disorders, and Sedative-, Hypnotic- or Anxiolytic-Related Disorders. 2) Attention-Deficit and Disruptive Behavior Disorders. 3) Eating Disorders. 4) Personality Disorders including but not limited to Obsessive-Compulsive Personality Disorder. 5) Impulse-Control Disorders, comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt.

Abstract: A process for preparing an oxidation/reduction catalyst system includes providing a sol-gel precursor; providing a metal oxide wash coat mixture; and dispersing the sol-gel precursor in the metal oxide wash coat mixture to provide a dispersion of sol-gel precursor in metal oxide wash coat mixture. This dispersion of sol-gel precursor in metal oxide wash coat mixture is then deposited on a support, which is subsequently thermally-treated in an oxygen-containing environment to drive off volatiles and oxidize metallic components, thereby producing a thermally-treated support. Finally, a noble metal coating is applied to the thermally-treated support.

Abstract: A method of treating at least one symptom or condition associated with but not limited to: Sleep Disorders including but not limited to 1) Dyssomnia Disorders including but not limited to: a) Primary inomnia, b) Primary Hypersomnia, and c) narcolepsy; and 2) Parasomnias Disorders including but not limited to a) Nightmare Disorder, Sleep Terror Disorder and Sleepwalking Disorder, comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

Abstract: A method of treating at least one symptom or condition associated with but not limited to:, Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence including but not limited to Mental Retardation, Learning Disorders, Motor Skills Disorder, Communication Disoorders, Pervasive Developmental Disorders, Attention-Deficit and Disruptive Behavior Disorders, Feeding and Eating Disorders of Infancy or Early Childhood, Tic Disorders, and Elimination Disorders comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

Abstract: A method of treating at least one symptom or condition associated with but not limited to: Mood Disorders including but not limited to a) Depressive Disorders, including but not limited to Major Depressive Disorder and Dysthymic Disorder and b) Bipolar Depression and/or Bipolar mania including but not limited to Bipolar I Disorder, including but not limited to those with manic, depressive or mixed episodes, and Bipolar 11 Disorder, c) Cyclothymic Disorder, and d) Mood Disorder Due to a General Medical Condition comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

Abstract: A method of treating at least one symptom or condition associated with but not limited to: Anxiety Disorders including but not limited to Panic Disorder Without Agoraphobia, Panic Disorder With Agoraphobia, Agoraphobia Without History of Panic Disorder, Specific Phobia, Social Phobia, Obsessive-Compulsive Disorder, Postaumatic Stress Disorder, Acute Stress Disorder, Generalized Anxiety Disorder and Generalized Anxiety Disorder Due to a General Medical Condition comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

Abstract: A method of treating at least one symptom or condition associated with but not limited to: 1) Schizophrenia and other Psychotic Disorders including but not limited to Psychotic Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and Psychotic Disorder Due to a General Medical Condition and 2) Dementia and other Cognitive Disorders comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

Abstract: The present invention provides a method of managing telecommunications networks through an Operations Support Services (OSS) client and templates. Using an OSS client and various provisioning templates a network manager may interactively provision network services in one or more network devices, in one or more networks, through one or more network management systems. A network manager may interactively establish connections between an OSS client and an NMS server and network device, or the network manager may employ a control template to non-interactively establish these connections. The client/server architecture allows network managers to access multiple different network management servers through multiple OSS clients, and an OSS client may be downloaded from a web accessible server to provide “manage anywhere” flexibility.

Abstract: The invention described herein involves a novel approach to the production of oxidation/reduction catalytic systems. The present invention serves to stabilize the tin oxide reducible metal-.oxide coating by co-incorporating at least another metal-oxide species, such as zirconium. In one embodiment, a third metal-oxide species is incorporated, selected from the group consisting of cerium, lanthanum, hafnium, and ruthenium. The incorporation of the additional metal oxide components serves to stabilize the active tin-oxide layer in the catalytic process during high-temperature operation in a reducing environment (e.g., automobile exhaust). Moreover, the additional metal oxides are active components due to their oxygen-retention capabilities. Together, these features provide a mechanism to extend the range of operation of the tin-oxide-based catalyst system for automotive applications, while maintaining the existing advantages.

Abstract: New mutations have been found in the BRCA1 gene. The mutations are located at nucleotide numbers 421-2, 815, 903, 926, 1506, 2034, 2428, 3888, 3904, 4164, 4643, 5053, 5150, 5210, or 5396+40 of the gene sequence of BRCA1. A process for identifying a sequence variation in a BRCA1 polynucleotide sequence is disclosed. The identification process includes allele specific sequence-based assays of known sequence variations. The methods can be used for efficient, and accurate detection of a mutation in a test BRCA1 gene sample.

Abstract: A bio-injectable drug composition which provides long term drug release. The drug composition is made up of a pharmaceutically active agent in a biodegradable polymer matrix, where the polymer matrix is a solid at temperatures in the range 20.degree. to 37.degree. C. and is flowable at temperatures in the range 38.degree. to 52.degree. C.

Abstract: A quantity of reagent grade tin metal or compound, chloride-free, and high-surface-area silica spheres are placed in deionized water, followed by deaerating the mixture by boiling and adding an oxidizing agent, such as nitric acid. The nitric acid oxidizes the tin to metastannic acid which coats the spheres because the acid is adsorbed on the substrate. The metastannic acid becomes tin-oxide upon drying and calcining. The tin-oxide coated silica spheres are then placed in water and boiled. A chloride-free precious metal compound in aqueous solution is than added to the mixture containing the spheres, and the precious metal compound is reduced to a precious metal by use of a suitable reducing agent such as formic acid. Very beneficial results have been obtained using the precious metal compound tetraammine platinum(II) hydroxide.